

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



星悦康旅股份有限公司
Starjoy Wellness and Travel Company Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 3662)

**CHANGES OF DIRECTORS
AND AUTHORISED REPRESENTATIVE
AND
CHANGE IN COMPOSITION OF BOARD COMMITTEES**

(1) RESIGNATION OF THE CHAIRMAN OF THE BOARD, NON-EXECUTIVE DIRECTOR AND THE CHAIRMAN OF THE NOMINATION COMMITTEE OF THE COMPANY

The board (the “**Board**”) of directors (the “**Directors**”) of Starjoy Wellness and Travel Company Limited (formerly known as Aoyuan Healthy Life Group Company Limited) (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Li Huiqiang (李惠強先生) (“**Mr. Li**”) has tendered his resignation and will cease to act as the chairman of the Board, a non-executive Director and the chairman of the nomination committee of the Company (the “**Nomination Committee**”) with effect from 17 May 2024 due to personal health issues.

Mr. Li has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that is required to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) and/or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its gratitude to Mr. Li for his invaluable support to the Group during his tenure of office.

(2) RESIGNATION OF EXECUTIVE DIRECTOR, AUTHORISED REPRESENTATIVE AND A MEMBER OF THE REMUNERATION COMMITTEE OF THE COMPANY

The Board further announces that Mr. Cheng Siu Fai (鄭少輝先生) (“**Mr. Cheng**”) has tendered his resignation and will cease to act as an executive Director, a member of the remuneration committee of the Company (the “**Remuneration Committee**”) and an authorised representative (the “**Authorised Representative**”) under the Rule 3.05 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) with effect from 17 May 2024 due to his other work commitments.

Mr. Cheng has confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that is required to be brought to the attention of the Shareholders and/or the Stock Exchange.

The Board would like to express its gratitude for the invaluable contribution of Mr. Cheng to the Group during his tenure of office.

(3) APPOINTMENTS OF EXECUTIVE DIRECTORS

Following Mr. Li’s and Mr. Cheng’s resignations, the Board is pleased to announce the following changes of the members of the Board with effect from 17 May 2024:

- (i) Dr. Wang Jiren (王吉人博士) (“**Dr. Wang**”) has been appointed as the chairman of the Board, an executive Director, the president of the Group, the chairman of the Nomination Committee, a member of the Remuneration Committee and the Authorised Representative. Dr. Wang is primarily responsible for coordinating the general management and operation of the Group; and
- (ii) Ms. Liang Jinrong (梁金蓉女士) (“**Ms. Liang**”) has been appointed as an executive Director and the chief financial officer of the Group and is primarily responsible for the overall financial and accounting affairs and treasury management of the Group.

The biographical details of each of Dr. Wang and Ms. Liang are as follows:

(a) Dr. Wang

Dr. Wang, aged 41, obtained a doctoral degree of Hotel and Tourism Management at Hong Kong Polytechnic University in 2024; a master's degree of Regional Economics at Jinan University (暨南大學) in 2006; and a bachelor's degree in economics from Nankai University (南開大學) in 2004, majoring in international economics and trade. Dr. Wang possesses extensive experience in business operations and company management. Since March 2019, Dr. Wang served as the vice president of the Group and is in charge of the operation and management of the Group's property management services and commercial operational services in the People's Republic of China (the "PRC"). Also, Dr. Wang is currently a director, supervisor, legal representative and general manager of certain subsidiaries of the Company.

(b) Ms. Liang

Ms. Liang, aged 49, graduated with a bachelor's degree in accounting from Henan Polytechnic University (河南理工大學) in 2007. Ms. Liang has over 28 years of experience in audit and financial management and is a registered accountant (non-practising) of Guangdong Provincial Institute of Certified Public Accountants of the PRC. Ms. Liang was qualified as a senior corporate compliance officer (高級企業合規師) from the China Enterprise Evaluation Association (中國企業評價協會) in 2023 and passed the national examination for intermediate accounting in 2005. Since October 2023, Ms. Liang served as the vice president of the Group. From December 2007 to October 2023, Ms. Liang held various positions in Aoyuan Corporation (Group) Ltd.* (奧園集團有限公司)#. From August 1995 to December 2004, Ms. Liang served as the deputy director of the accounting and finance department in the sub-branch of the Agricultural Bank of China in Shanyang District of Jiaozuo City in Henan Province, the PRC.

Each of Dr. Wang and Ms. Liang has entered into a service contract with the Company for an initial term of three (3) years commencing from 17 May 2024 which is renewable automatically and can be terminated by either party giving three (3) months' prior written notice. Each of Dr. Wang and Ms. Liang is eligible for re-election at the next following annual general meeting of the Company after their appointments and be subject to retirement by rotation and re-election at least once every three years at the annual general meeting of the Company in accordance with the articles of association of the Company.

Each of Dr. Wang and Ms. Liang is entitled to receive a salary of RMB1,980,000 and RMB1,800,000 per annum respectively, which is commensurate with his/her duties and responsibilities in the Group and the prevailing market situation and discretionary bonuses pegged to his/her performance.

As at the date of this announcement and save as disclosed above, neither Dr. Wang nor Ms. Liang:

- (i) has held any other major appointments and qualifications or directorships in other listed companies in Hong Kong or overseas in the three years preceding the date of this announcement;
- (ii) holds any other position in the Company or other members of the Group;
- (iii) has any relationship with any Directors, senior management, substantial shareholders or controlling shareholders (as defined under the Listing Rules) of the Company; and
- (iv) has any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of Laws of Hong Kong).

Save as disclosed above, there is no other information that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules nor any other matters in relation to the appointments of Dr. Wang and Ms. Liang that needs to be brought to the attention of the Shareholders and/or the Stock Exchange.

The Board would like to express its recognition of Dr. Wang and Ms. Liang's past work performance in the Group and extend its warmest welcome to Dr. Wang and Ms. Liang for joining the Board.

By the order of the Board
Starjoy Wellness and Travel Company Limited
Jiang Nan
Non-executive Director

Hong Kong, 17 May 2024

* *All of the English titles or names of the entities in the PRC, as well as certain items contained in this announcement have been included for identification purpose only. If there is any inconsistency, the Chinese titles or names shall prevail.*

Aoyuan Corporation (Group) Ltd. (奧園集團有限公司) is a wholly-owned subsidiary of China Aoyuan Group Limited, a company listed on the Main Board of the Stock Exchange (stock code: 3883) and a substantial shareholder of the Company.*

As at the date of this announcement, the executive Directors are Dr. Wang Jiren and Ms. Liang Jinrong; the non-executive Directors are Mr. Ruan Yongxi, Mr. Zhu Yunfan and Ms. Jiang Nan; and the independent non-executive Directors are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.